The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sergeeva N.S.

Russian University of Peoples' Friendship

Skachkova T.E.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow

Marshutina N.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Alekseev B.Ia.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Clinical significance of PSA-associated tests in the diagnosis and staging of prostate cancer

Authors:

Sergeeva N.S., Skachkova T.E., Marshutina N.V., Alekseev B.Ia., Kaprin A.D.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2018;7(1): 55‑67

DOI: 10.17116/onkolog20187155-67

Read: 13944 times

Download PDF (RU)
Contact the author
Table of contents

CLINICAL SIGNIFICANCE OF PSA-ASSOCIATED TESTS IN THE DIAGNOSIS AND STAGING OF PROSTATE CANCER
CLINICAL SIGNIFICANCE OF PSA-ASSOCIATED TESTS IN THE DIAGNOSIS AND STAGING OF PROSTATE CANCER

To cite this article:

Sergeeva NS, Skachkova TE, Marshutina NV, Alekseev BIa, Kaprin AD. Clinical significance of PSA-associated tests in the diagnosis and staging of prostate cancer. P.A. Herzen Journal of Oncology. 2018;7(1):55‑67. (In Russ.)
https://doi.org/10.17116/onkolog20187155-67

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Pote­ntial of specialized diet therapy in redu­cing toxic mani­festations in patients with meta­static castration-resistant prostate cancer with bone meta­stases during radionuclide therapy with radium chlo­ride [223Ra]. P.A. Herzen Journal of Onco­logy. 2024;(6):33-41
Remote resu­lts of treatment of patients with prostate cancer who unde­rwent radiation therapy in a combined version. P.A. Herzen Journal of Onco­logy. 2025;(3):14-19
Patterns of CAF expression in tumors of the geni­tourinary system. Russian Journal of Archive of Pathology. 2024;(6):28-35
Epidemiology and prevention of prostate cancer. Russian Journal of Preventive Medi­cine. 2025;(7):111-118
Cost-effectiveness analysis of triptorelin therapy for patients with prostate cancer in state healthcare system of the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):83-92
Abstract:

The review presents a historical account of the discovery and current ideas on the serological tumor-associated marker prostate-specific antigen (PSA), its place in oncology: in the use for differential diagnosis and also in screening aimed at active early detection of prostate cancer (PC). It describes the biochemical characteristics of PSA, its functions, as well as the most informative indices (the ratio of PSA to prostate volume (PSA density, PSA-D), PSA velocity (PSA-V), and free/total PSA ratio (%fPSA)). The paper discusses the possibilities of using the precursors of PSA, in particular [-2]proPSA, %[-2]proPSA, as well as %proPSA and prostate health index (PHI) in the clarifying diagnosis of PC and in the differentiation of its indolent forms from aggressive ones. It provides information on PC risk calculators, including PSA tests.

Keywords:

prostate specific antigen (PSA)
[-2]proPSA
%[-2]proPSA
prostate health index (PHI)
prostate cancer

Authors:

Sergeeva N.S.

Russian University of Peoples' Friendship

Skachkova T.E.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow

Marshutina N.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Alekseev B.Ia.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Close metadata

References:

  1. Hernandez J, Thompson IM. Prostate specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer. 2004;101(5):894-904. https://doi.org/10.1002/cncr.20480
  2. Teahan S.J, Klotz LH. Current role of prostate-specific antigen kinetics in managing patients with prostate cancer. BJU Int. 2006;97(3):451-455. https://doi.org/10.1111/j.1464-410X.2006.05958.x
  3. Rao AR, Motiwala HG, Karim OMA. The discovery of prostate-specific antigen. BJU Int. 2008;101(1):5-10. https://doi.org/10.1111/j.1464-410X.2007.07138.x
  4. Li TS, Behrman SJ. The sperm- and seminal plasma-specific antigens of human semen. Fertil Steril. 1970;21(7):565-573. https://doi.org/10.1016/S0015-0282(16)37627-0
  5. Shulman S, Bronson P. Immunochemical studies on human seminal plasma. II. The major antigens and their fractionation. J Reprod Fertil. 1969;18:481-491.
  6. Hara M, Koyanagi Y, Inoue T, Fukuyama T. Some physico-chemical characteristics of seminoprotein, an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII Nihon Hoigaku Zasshi. 1971;25:322-324. (Abstract in Japanese).
  7. Flocks RH, Bandhaur K, Patel C, Begley BJ. Studies on spermagglutinating antibodies in antihuman prostate sera. J Urol. 1962;87(3):475-478. https://doi.org/10.1016/S0022-5347(17)64982-6
  8. Hara M, Inoue T, Koyanagi Y, Gotoh J, Yamazaki H, Fukuyama T. Preparation and immunoelectrophoretic assessment of antisera to human seminal plasma. Nippon Hoigaku Zasshi. 1966;20:356. (Abstract in Japanese).
  9. Ablin RJ. Immunologic studies of normal, benign, and malignant human prostatic tissue. Cancer. 1972;29:1570-1574.
  10. Ablin RJ, Soanes WA, Bronson P, Witebsky E. Precipitating antigens of the normal human prostate. J Reprod Fertil. 1970;22(3):573-574.
  11. Ablin RJ, Bronson P, Soanes WA, Witebsky E. Tissue- and species-specific antigens of normal human prostatic tissue. J Immunol. 1970;104(6):1329-1339.
  12. Sensabaugh GF. Isolation and characterization of a semen-specific protein from human seminal plasma: a potential new marker for semen identification. J Forensic Sci. 1978;23(1):106-115.
  13. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol. 1979;17(2):159-163.
  14. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen 1979. J Urol. 2002;167(2,Pt2):960-964.
  15. Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM. A prostate antigen in sera of prostatic cancer patients. Cancer Res. 1980;40(7):2428-2432.
  16. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909-916. https://doi.org/10.1056/NEJM198710083171501
  17. Lilja H, Oldbring J, Rannevik G, Laurell C B. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest. 1987;80(2):281-285. https://doi.org/10.1172%2FJCI113070
  18. Diamandis EP, Yu H. Nonprostatic sources of prostate-specific antigen. Urol Clin North Am. 1997;24(2):275-282.
  19. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein. Cancer Res. 1997;57(15):3111-3114.
  20. Mikolajczyk SD, Rittenhouse HG. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med. 2003;2(2):86-91.
  21. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995;154(2,Pt 1):407-413.
  22. Park SC, Shin YS, Zhang LZ, Kim DS, Kim SZ, Park NC, et al. Prospective investigation of change in the prostate-specific antigens after various urologic procedures. Clin Interv Aging. 2015;29(10):1213-1218. https://doi.org/10.2147%2FCIA.S84570
  23. Ellis WJ, Brawer MK. Repeat prostate needle biopsy: who needs it? J Urol. 1995;153(5):1496-508.
  24. Chissov VI, Alekseev BYa, Rusakov IG, eds. Oncourology. National guidelines (Onkourologiya. Natsional’noe rukovodstvo). Moscow: GEOTAR-Media; 2012. (In Russ.)
  25. Sher YP, Chou CC, Chou RH, Wu HM, Wayne Chang WS, Chen CH, et al. Human kallikrein 8 protease confers a favorable clinical outcome in non-small cell lung cancer by suppressing tumor cell invasiveness. Cancer Res. 2006;66(24):11763-11770. https://doi.org/10.1158/0008-5472.CAN-06-3165
  26. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA. 1999;281(15):1395-400.
  27. Wang TJ, Slawin KM, Rittenhouse HG, Millar LS, Mikolajczyk SD. Benign prostatic hyperplasia-associated prostate-specific antigen (BPSA) shows unique immunoreactivity with anti-PSA monoclonal antibodies. Eur J Biochem. 2000;267(13):4040-4045.
  28. Webber MM, Waghray A, Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res. 1995;1(10):1089-1094.
  29. Pushkar’ DYu, Rasner PI. Differential diagnosis of cancer and benign prostatic hyperplasia. Russkii meditsinskii zhurnal. 2014;22(17):1298-1303. (In Russ.)
  30. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC et al. Comparison of digital rectal examination and serum prostate specific antigen (PSA) in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol. 1994;151(5):1283-1290.
  31. Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamkar VA, Fritsche HA HA Jr. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. J Urol. 2001;165(3):757-760.
  32. Catalona WJ, Ramos CG, Carvalhal GF, Yan Y. Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology. 2000;55(6):791-805.
  33. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA. 1997;277(18):1452-1455.
  34. Smith DS, Catalona WJ, Herschman JC. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA. 1996;276(16):1309-13015.
  35. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224. https://doi.org/10.1056/NEJMoa030660
  36. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA. 1993;270(7): 860-864.
  37. Collins GN, Lee RJ, McKelvie GB, Rogers AC, Hehir M. Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Br J Urol. 1993;71(4):445-50.
  38. Catalona WJ, Smith DS. Comparison of different serum prostate specific antigen measures for early prostate cancer detection. Cancer. 1994;74(5):1516-1518.
  39. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004;172(4,Pt1):1297-1301.
  40. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909-916. https://doi.org/10.1056/NEJM198710083171501
  41. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992;147(3,Pt 2):815-816.
  42. Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, Patel A, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology. 2002; 56(2):255-60.
  43. Allan RW, Sanderson H, Epstein JI. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol. 2003;170(2,Pt1):370-372. https://doi.org/10.1097/01.ju.0000074747.72993cb
  44. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostatespecific antigen levels in men with and without prostate disease. JAMA. 1992;267(16):2215-2220.
  45. Sun L, Moul JW, Hotaling JM, Rampersaud E, Dahm P, Robertson C, et al. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU Int. 2007;99(4):753-757. https://doi.org/10.1111/j.1464-410X.2006.06682.x
  46. Raaijmakers R, Blijenberg BG, Finlay JA, Rittenhouse HG, Wildhagen MF, Roobol MJ, et al. Prostate cancer detection in the prostate specific antigen range of 20 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol. 2004;171(6, Pt1):2245-2249.
  47. Raaijmakers R, Wildhagen MF, Ito K, Pàez A, de Vries SH, Roobol MJ, et al. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology. 2004;63(2):316-320. https://doi.org/10.1016/j.urology.2003.09.028
  48. Berger AP, Deibl M, Strasak A, Bektic J, Pelzer AE, Klocker H, et al. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer. Urology. 2007;69(1):134-138. https://doi.org/10.1016/j.urology.2006.09.018
  49. Loeb S, Sutherland DE, D’Amico AV, Roehl KA, Catalona WJ. PSA velocity is associated with Gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. Urology. 2008;72(5):1116-1120. https://doi.org/10.1016/j.urology.2008.01.082
  50. D’Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351(2):125-135. https://doi.org/10.1056/NEJMoa032975
  51. P’yanykh PP, Vorob’ev NV, Nyushko KM. Monitoring of PSA dynamics and PSA velocity in prostate cancer patients after radical prostatectomy. Onkourologiya. 2007;(3):68-72. (In Russ.)
  52. Kawachi MH. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: prostate cancer early detection (v.2.2007). http://www. nccn.org/professionals/physician gls/PDF/prostate_detection.pdf
  53. Lilja H, Stenman UH. Assay of free and complexed prostate-specific antigen (PSA). Patent US 5939533 A. Publ.17.08.1999
  54. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279(19):1542-1547.
  55. Partin AW, Brawer MK, Subong EN, Kelley CA, Cox JL, Bruzek DJ, et al. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Dis. 1998;1(4):197-203. https://doi.org/10.1038/sj.pcan.4500232
  56. Mikolajczyk SD, Grauer LS, Millar LS, Hill TM, Kumar A, Rittenhouse HG, et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology. 1997;50(5):710-714. https://doi.org/10.1016/S0090-4295(97)00449-4
  57. Sokoll LJ, Chan DW, Mikolajczyk SD, Rittenhouse HG, Evans CL, Linton HJ, et al. Proenzyme PSA for the early detection of prostate cancer in the 2.5—4.0 ng/ml total PSA range: preliminary analysis. Urology. 2003;61(2):274-276.
  58. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Amirkhan A, et al. Serum proPSA improves cancer detection compared to free and complexed PSA in men with PSA values from 2 to 4 ng/ml. J Urol. 2003;170(6,Pt1):2181-2185. https://doi.org/10.1097/01.ju.0000095460.12999.43
  59. Sidorenkov AV, Govorov AV, Sadchenko AV. Diagnostic significance [-2] proPSA and PHI (literature review). Onkourologya. 2014;(4):87-95. (In Russ.)
  60. Chan TY, Mikolajczyk SD, Lecksell K, Shue MJ, Rittenhouse HG, Partin AW, et al. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology. 2003;62(1):177-181.
  61. Mikolajczyk SD, Catalona WJ, Evans CL, Linton HJ, Millar LS, Marker KM, et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem. 2004;50(6):1017-1025. https://doi.org/10.1373/clinchem.2003.026823
  62. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Horninger W, et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol. 2004;171(6,Pt1):2239-2244.
  63. Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda MG, et al. [-2] proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol. 2008;180(2):539-543. https://doi.org/10.1016/j.juro.2008.04.015
  64. Le BV, Griffin CR, Loeb S, Carvalhal GF, Kan D, Baumann NA, et al. [-2] pro-PSA is more accurate than total and free PSA in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol. 2010;183(4):1355-1359. https://doi.org/10.1016%2Fj.juro.2009.12.056
  65. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, MD, Bangma CH, et al. A multi-center study of [-2]pro-prostate-specific antigen (PSA) in combination with PSA and Free PSA for prostate cancer detection in the 2.0 to 10.0 ng/mL PSA range. J Urol. 2011;185(5):1650-1655. https://doi.org/10.1016%2Fj.juro.2010.12.032
  66. Guazzoni G, Lazzeri M, Nava L, Lughezzani G, Larcher A, Scattoni V, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol. 2012;61(3):455-466. https://doi.org/10.1016/j.eururo.2011.10.038
  67. Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, Maccagnano C, et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol. 2011;60(2):214-222. https://doi.org/10.1016/j.eururo.2011.03.052
  68. Fossati N, Buffi NM, Haese A, Stephan C, Larcher A, McNicholas T, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer: Results from a Multicentric European Prospective Study. Eur Urol. 2015;68(1):132-1328. https://doi.org/10.1016/j.eururo.2014.07.034
  69. Lazzeri M, Haese A, Abrate A, de la Taille A, Redorta JP, McNicholas T, et al. Clinical performance of serum prostatespecific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int. 2013;112(3):313-321. https://doi.org/10.1111/bju.12217
  70. Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2—10 ng/ml: A Multicentric European Study. Eur Urol. 2013;63(6):986-994. https://doi.org/10.1016/j.eururo.2013.01.011
  71. Drost FJ, Alberts A. Prostate cancer research international: active surveillance of early prostate cancer. Dutch Trial Register ID: NTR1718. 2014. https://www.prias-project.org/
  72. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011;29(16):2185-2190. https://doi.org/10.1200/JCO.2010.32.8112
  73. Sanda M. Evaluation of the Prostate Health Index (PHI) for improving prostate cancer detection and identification of clinically significant prostate cancer in the 4 to 10 ng/mL PSA range. In: Proceedings of American Urological Association Annual Meeting. San Diego; 2013.
  74. Gvozdik EYu. Sovremennye podkhody k otsenke riska nalichiya raka predstatel’noi zhelezy: novyi marker -2proPSA i indeks zdorov’ya prostaty PHI. In: Nauchno-obrazovatel’nyi forum «Laboratornaya meditsina: tekhnologicheskii potentsial, rol’ v lechebnom protsesse i progresse klinicheskoi nauki i praktiki». OOO «Bekmen Kul’ter». (In Russ.) http://www.ramld.ru/userfiles/file/Belgorod%202016/GvozdikBelgorod.pdf
  75. Pushkar’ DYu, ed. Klinicheskoe ispol’zovanie Indeksa Zdorov’ya Prostaty (PHI) v diagnostike raka predstatel’noi zhelezy. Metodicheskie rekomendatsii. Posobie dlya vrachei. 2nd ed. Moscow: Triada; 2015. (In Russ.)
  76. Carroll PR. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: prostate cancer early detection 2014. http://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf
  77. Gutierrez A. Food and drug administration review of access hybritech p2PSA. 2012. http://www.accessdata.fda.gov/cdrh_docs/pdf9/p090026a.pdf
  78. Alyaev YuG, Glybochko PV, Pushkar’ DYu, eds. Urologiya. Rossiiskie klinicheskie rekomendatsii. Moscow: GEOTAR-Media; 2016. (In Russ.)
  79. Ankerst DP, Hoefler J, Bock S, Goodman PJ, Vickers A, Hernandez J, et al. The prostate cancer prevention trial risk calculator 2.0 for the prediction of low-versus high-grade prostate cancer. Urology. 2014;83(6):1362-1367. https://doi.org/10.1016/j.urology.2014.02.035
  80. Ankerst DP, Hoefler J, Bock S, Goodman PJ, Vickers A, Hernandez J, et al. Individualized Risk Assessment of Prostate Cancer (PCPTRC 2.0). Konfiguratsiya programmy ot 2017 g. http://myprostatecancerrisk.com/
  81. Kal’kulyatory riska raka prostaty №№1-6. Russkaya versiya. Rotterdam: Fond issledovanii po raku prostaty (FIRP); 2017. (In Russ.) https://pca-risk-calculator.ru/seven-prostate-cancer-risk-calculators
  82. Prostate Cancer Risk Calculators №№1-6. English version. Rotterdam: The Prostate Cancer Research Foundation (SWOP); 2017. https://www.prostatecancer-riskcalculator.com
  83. The European Randomized study of Screening for Prostate Cancer (ERSPC). 2014. http://www.erspc.org/
  84. Bul M, Delongchamps NB, Steyerberg EW, de la Roza G, van Leeuwen PJ, Zhu X, et al. Updating the prostate cancer risk indicator for contemporary biopsy schemes. Can J Urol. 2011;18(2):5625-5629.
  85. Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol. 2012;61(3):577-583. https://doi.org/10.1016/j.eururo.2011.11.012
  86. Trottier G, Roobol MJ, Lawrentschuk N, Boström PJ, Fernandes KA, Finelli A, et al. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. BJU Int. 2011;108(8,Pt2):237-244. https://doi.org/10.1111/j.1464-410X.2011.10207.x
  87. Roobol MJ, Vedder MM, Nieboer D, Houlgatte A, Vincendeau S, Lazzeri M, et al. Comparison of two prostate cancer risk calculators that include the prostate health index. Eur Urol Focus. 2015;1(2):185-190. https://doi.org/10.1016/j.euf.2015.06.004
  88. Vorob’ev AV. General screening questions. Prakticheskaya onkologiya. 2010;11(2):53-59. (In Russ.)
  89. 89.Mandel JS, Smith R, De Vita VT, et al. Principles of cancer screening. DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer. Principles & practice of oncology. Lippincott Williams & Wilkins; 2008;659-676.
  90. Mottet N, Bellmunt J, Briers T, Bolla M, Cornford P, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618-629. https://doi.org/10.1016/j.eururo.2016.08.003
  91. Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA. 2014;311(11):1143-1149. https://doi.org/10.1001/jama.2014.2085
  92. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125-132. https://doi.org/10.1093/jnci/djr500
  93. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079-1092. https://doi.org/10.1016/j.eururo.2012.02.054
  94. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res. 2009;53(2):171-184. https://doi.org/10.1002/mnfr.200700511
  95. Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, et al. Prostate-cancer mortality in the USA and UK in 1975—2004: an ecological study. Lancet Oncol. 2008;9(5):445-452. https://doi.org/10.1016/S1470-2045(08)70104-9
  96. Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19(2):175-181. https://doi.org/10.1007/s10552-007-9083-8
  97. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schönitzer D, et al. Prostate cancer mortality after introduction of prostate-specifi c antigen mass screening in the Federal State of Tyrol, Austria. Urology. 2001;58(3):417-24.
  98. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725-732. https://doi.org/10.1016/S1470-2045(10)70146-7
  99. Sandblom G, Varenhorst E, Löfman O, Rosell J, Carlsson P. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol. 2004;46(6):717-723. https://doi.org/10.1016/j.eururo.2004.08.011
  100. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR; et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-1319. https://doi.org/10.1056/NEJMoa0810696
  101. Grubb RL 3rd, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 2008;102(11):1524-1530. https://doi.org/10.1111/j.1464-410X.2008.08214.x
  102. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366(11):981-990. https://doi.org/10.1056/NEJMoa1113135
  103. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027-2035. https://doi.org/10.1016/S0140-6736(14)60525-0
  104. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and Prostate-Cancer Mortality in a Randomized European Study. N Engl J Med. 2009;360(13):1320-1328. https://doi.org/10.1056/NEJMoa0810084
  105. Ruzhanskaya AV. Innovatsii v otsenke riska razvitiya raka predstatel’noi zhelezy. Beckman Coulter; 2013. (In Russ.) http://diama.ru/sites/default/files/0_materials/Ruzanskaya_Innovation.pdf
  106. Shaderkina VA, Verovskii VE, Dudchenko GP, Zaitsev VG, Fomina TV, Murzina NP. Screening of prostate cancer: TO BE OR NOT TO BE? Daidzhest Urologii. 2014;(6):8-19. (In Russ.)
  107. Reznichenko MF. Algorithms for assessing the economic efficiency of laboratory technologies. Klinicheskaya laboratornaya diagnostika. 2013;(12):56-60. (In Russ.)
  108. Sivkov AV, Chernyshev IV, Perepanova TS, Oshchepkov VN, Keshishev NG. Skrining raka predstatel’noi zhelezy. Metodicheskie rekomendatsii № 543-PD/623. Moscow: FGU Nauchno-issledovatel’skii institut urologii ROSZDRAVA, 28 December 2006. (In Russ.)
  109. Knyazev EN, Fomicheva KA, Nyushko KM, Kaprin AD, Alekseev BYa, Shkurnikov MYu. Actual issues of molecular diagnostics of prostate cancer. Onkourologiya. 2014;(4):14-22. (In Russ.)
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.